Lam Research -- 8.2/10 -- $218.44

Lam Research is the dominant supplier of etch and deposition equipment to the global semiconductor industry, holding approximately 50% share in etch and 30% in deposition. The company operates within a tight oligopoly alongside Applied Materials (AMAT), Tokyo Electron (TEL), and KLA Corporation (KLAC). Barriers to entry are extreme: decades of process knowledge, deep customer co-development relationships, and switching costs that compound with each technology node. Every major scaling trend -- vertical NAND stacking, gate-all-around (GAA) transistors, 3D DRAM, HBM, and advanced packaging -- increases etch and deposition intensity, expanding the serviceable addressable market (SAM) from the low-30s to the high-30s as a percentage of wafer fabrication equipment (WFE) spending.

CY2025 was a record year across all financial metrics. Calendar year revenue reached $20.6B (+27% YoY), non-GAAP operating margins hit 34-35% (post-Novellus highs, ahead of the Investor Day model), and free cash flow came in at $5.4B (FCF/revenue ~29%). Revenue has grown for 10 consecutive quarters. Management has beaten revenue and EPS guidance midpoints every quarter for at least 5 consecutive quarters, with EPS beats of 4-11% becoming the norm. The installed base crossed 100,000 chambers, powering CSBG (Customer Support Business Group) to a record $7.2B.

The technology roadmap creates multiple overlapping growth vectors. GAA migration adds ~$1B incremental SAM per 100K WSPM. The $40B+ NAND upgrade opportunity is tracking ahead of schedule with upgrade revenue up 90%+ YoY in CY2025. Advanced packaging (SABRE 3D, TSV etch) is expected to grow 40%+ in CY2026. Halo ALD Moly is the production tool of record at multiple NAND customers for 3+ consecutive nodes and expanding into foundry/logic. Backside power delivery -- still early -- represents the next major SAM expansion driver. Management guides CY2026 WFE to ~$135B (+23% YoY), constrained by available clean room space, with visibility into a multi-year build-out continuing into CY2027+.

LRCX receives a composite score of 8.2/10, reflecting a best-in-class semi equipment company riding the most powerful WFE upcycle in the industry history -- with multiple overlapping technology vectors expanding its SAM and driving share gains at every node.

Bull case: The technology roadmap is exceptionally deep. GAA, advanced packaging, NAND upgrades, ALD Moly, and backside power delivery each independently expand etch and deposition intensity. CY2026 WFE is guided to ~$135B (+23% YoY), and management sees a multi-year build-out continuing into CY2027+. The Investor Day target to more than double revenue and profit over five years is credible -- the company is already hitting its 34-35% operating margin model at ~$21B in revenue, well below the $25-27B target range. CSBG at $7.2B with 100K+ installed chambers provides a growing recurring revenue base. On FY2027E EPS of ~$7.00, the forward P/E compresses to ~31x.

Bear case: China remains 35% of revenue and is subject to regulatory whiplash, with the 50% affiliate rule impacting ~$600M in CY2026. WFE is inherently cyclical, and $135B would be a massive step-up that depends on sustained AI capex. Non-GAAP gross margins at 49-50% may face headwinds as China mix normalizes. At ~41x forward earnings, the valuation leaves limited room for multiple expansion and assumes near-flawless execution.

Key differentiator: The combination of oligopoly positioning (~50% etch, ~30% deposition), SAM expansion at every node, 10 consecutive quarters of revenue growth, a management team that consistently beats guidance, and a $40B+ NAND upgrade cycle tracking ahead of schedule creates a rare compounding setup. The primary question is not quality -- it is whether the cyclical tailwinds sustain long enough to justify the premium multiple.

Key catalysts and monitoring points:

• CY2026 WFE delivery vs. ~$135B guide: This is the single most important variable. Clean room space constraints may cap CY2026 but set up CY2027 well. Track quarterly WFE commentary for any revisions.
• China revenue trajectory: Declined from 43% (CY25Q3) to 35% (CY25Q4). Monitor whether it continues normalizing or surprises to the upside again. The 50% affiliate rule impact (~$600M) is a known headwind -- watch for further regulatory tightening.
• Gross margin sustainability: Non-GAAP GMs at 49-50% are at post-Novellus highs. CY26Q3 guided to 49% +/- 1pp. Track whether Malaysia manufacturing efficiency offsets the China mix headwind.
• NAND upgrade cycle pace: $40B+ opportunity tracking ahead of schedule. Watch for continued acceleration as AI inference creates new demand for non-volatile context memory. Management estimates every 2-3M accelerators sold adds ~1pp to NAND bit demand growth.
• Advanced packaging growth: Expected 40%+ in CY2026. HBM3e to HBM4/4e transition with up to 16-layer stacking is a major tailwind. Track SABRE 3D and TSV etch momentum.
• GAA adoption cadence: Aqara conductor etch tool doubled its installed base in CY2025. Expect ~2x more applications in next-gen GAA devices. Watch for new tool-of-record wins.
• Capital return: Returned 85% of FCF in CY2025. Share count declining ~3.2% over 5 quarters. Monitor buyback pace and dividend trajectory.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Concerns, Catalysts & Risks -- full analysis

Buy at current levels -- Lam Research is a high-quality compounder entering the strongest WFE upcycle in industry history, with multiple technology vectors expanding its SAM and a management team that consistently under-promises and over-delivers. At $218.44 (15% below ATH), the stock trades at ~41x FY2026E earnings and ~31x FY2027E earnings. The premium valuation is justified by the earnings growth trajectory (+32% revenue CAGR FY2026-FY2027E) but leaves limited room for multiple expansion.

The setup for CY2026-2027 is exceptionally strong. WFE guided to $135B with Lam expected to outperform through SAM expansion and share gains. The NAND upgrade cycle ($40B+ opportunity), GAA migration, advanced packaging, and CSBG flywheel (100K+ chambers) provide multiple independent growth drivers. Management at the February 2025 Investor Day targeted more than doubling revenue and profit over five years -- and the company is already running ahead of its own operating margin model.

Risk management: The main risks are China regulatory exposure (35% of revenue, ~$600M affiliate rule impact), WFE cyclicality (the current upcycle depends on sustained AI capex), and gross margin pressure from China mix normalization. A pullback to the $180-$200 range (~35x FY2027E) on macro or geopolitical headlines would offer an even more compelling entry. For existing holders, the fundamental trajectory supports continued ownership. For new positions, the quality justifies a full-sized entry with the understanding that semi equipment multiples compress if the cycle turns.